Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rhei Pharmaceuticals, a specialty pharmaceutical company, has received approval from the State Food and Drug Administration in China for the marketing of its first product, the Drs Hans Schreuder scar treatment product, as well as three companion products that are part of the Drs Hans Schreuder vision for health skin care line.
Subscribe to our email newsletter
The Drs Hans Schreuder scar treatment product is expected to contain soya extract, which is known to even out skin tone and texture. The cream is also expected to contain natural vitamin E, natural lactic acid, and rice and camomile extracts. These nutrients reduce scars while nourishing and moisturizing the skin, the company said.
Rhei Pharmaceuticals is expected to guide the marketing message and marketing support for the product, and is currently negotiating a sales and distribution agreement for hospital and pharmacy detailing with one of the distributors of healthcare products in China.
Geert Cauwenbergh, CEO and chairman of Rhei Pharmaceuticals, said: We are very pleased with this first approval of a Rhei product in China. We licensed the Drs Hans Schreuder natural skin care line in February 2008 and this approval underscores Rhei’s capability to bring products through the Chinese development and regulatory system in an efficient manner.